A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
NCT05615636
Recruiting
To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Hodgkin Lymphoma, B-Cell Lymphoma, Relapsed B-cell NHL
Register for Updates
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
NCT05652868
Recruiting
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic NSCLC. MYTX-011 is in a class of medications called antibody drug conjugates (ADCs). MYTX-011 is composed of a pH-dependent anti-cMET antibody and the potent antimicrotubule drug monomethyl auristatin E (MMAE).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of California San Diego, La Jolla, California +54 locations
Conditions: NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Small Cell Lung Cancer, Advanced Non-Small Cell Non-Squamous Lung Cancer
Register for Updates
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
NCT05671510
Recruiting
The goal of this Phase 3 clinical trial is study the safety and efficacy of the nextgen anti-CTLA-4 antibody, gotistobart (ONC-392/BNT316), in patients with metastatic non-small cell lung cancer who have disease progressed on anti-PD-1/PD-L1 antibody based therapy. The study will test whether gotistobart, in comparison with chemotherapy agent docetaxel, could prolong the life for NSCLC patients. Patients will be randomized to be treated with either gotistobart or docetaxel, IV infusion, once eve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: XCancer/Dothan Hematology & Oncology - 1114, Dothan, Alabama +159 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
NCT05674799
Recruiting
The goal of this clinical trial is to test an enhanced version of the National Diabetes Prevention Program (NDPP-NextGen) that is tailored to young women in childbearing years. The investigators will recruit 360 women aged 18-39 years with overweight/obesity who are not currently pregnant, but likely to conceive within 24 months. Women will be randomized to NDPP-NextGen or a usual care control group. The NDPP-NextGen group will participate in the adapted NDPP online group class across 12 months,... Read More
Gender:
FEMALE
Ages:
Between 18 years and 39 years
Trial Updated:
06/26/2025
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Overweight or Obesity
Register for Updates
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
NCT05676931
Recruiting
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: University of Alabama at Birmingham (UAB), Birmingham, Alabama +57 locations
Conditions: Advanced Non-Small Cell Lung Cancer
Register for Updates
Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer
NCT05696782
Recruiting
This research study aims to determine what effects (good and bad) Durvalumab has on participants and their cancer with a "quick start" of Durvalumab within 14 days of finishing chemotherapy and radiation. The study will also determine the logistic barriers to the quick start of Durvalumab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina
Conditions: Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II
Register for Updates
Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors
NCT05724108
Recruiting
This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a rad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +24 locations
Conditions: Metastatic Neuroendocrine Tumor
Register for Updates
Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age
NCT05766839
Recruiting
A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia
Gender:
ALL
Ages:
11 years and below
Trial Updated:
06/26/2025
Locations: UF Health Pediatric Multispecialty Center, Jacksonville, Florida +11 locations
Conditions: Hyperkalemia
Register for Updates
Durability of Vaccine Responses
NCT05801978
Recruiting
The ability of the vaccines today to generate a long-lasting protection against infections varies greatly from one vaccine to another. The yellow fever vaccine (YF-17D) is one of the most successful vaccines ever developed, having been administered to over 600 million people globally. A single vaccination is known to induce durable protection over several decades. In contrast, the quadrivalent influenza vaccine (QIV) generates an immunity that wanes quickly with no long-lasting protection. Curre... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/26/2025
Locations: Emory University Hospital, Atlanta, Georgia +2 locations
Conditions: Vaccine Response
Register for Updates
Vascular MRI Evaluation in Giant Cell Arteritis (VEGA)
NCT05865054
Recruiting
The research study is being conducted to determine the utility of magnetic resonance imaging (MRI) in identifying inflammation of arteries supplying blood to the head, brain, and eyes. The target population includes patient with suspected giant cell arteritis (GCA; temporal arteritis).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/26/2025
Locations: 3400 Civic Center Blvd, Philadelphia, Pennsylvania
Conditions: Giant Cell Arteritis
Register for Updates
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
NCT05895786
Recruiting
The purpose of the study is to understand how the study medicine PF-06823859 works in people with idiopathic inflammatory myopathies (DM and PM). These disorders cause inflammation that weakens the muscles that are important for movement and may also cause skin rash in people with DM. This study is seeking participants who: * Are 18 years of age or older or minimum legal adult age as defined per local regulation, whichever is greater * Have active DM or active PM. * Are receiving a stable dose... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/26/2025
Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Glendale, Glendale, Arizona +126 locations
Conditions: Myositis
Register for Updates
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
NCT05904028
Recruiting
Home optical coherence tomography- guided treatment versus treat and extend for the management of neovascular age-related macular degeneration.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/26/2025
Locations: Kent W. Small, MD, AMC, Glendale, California +55 locations
Conditions: Neovascular Age-related Macular Degeneration
Register for Updates